{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T13:18:56Z","timestamp":1785417536852,"version":"3.56.0"},"reference-count":47,"publisher":"Department of Medicine, Warren Alpert Medical School at Brown University","issue":"3","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>Heart failure with preserved ejection fraction (HFpEF) accounts for nearly half of all heart failure cases and remains a major source of morbidity and hospitalization, particularly among older adults with multiple comorbidities. HFpEF is characterized by diastolic dysfunction, ventricular stiffness, and impaired filling, driven by systemic inflammation, endothelial dysfunction, and myocardial fibrosis. Management is complicated by common comorbidities such as hypertension, type 2 diabetes, atrial fibrillation, chronic kidney disease, obesity, and coronary artery disease. Recent advances have expanded treatment options, with sodium-glucose cotransporter-2 (SGLT2) inhibitors demonstrating the strongest evidence for reducing heart failure hospitalizations and cardiovascular death. Additional therapies, including angiotensin receptor-neprilysin inhibitors (ARNIs), non-steroidal mineralocorticoid receptor antagonists (e.g., finerenone), and glucagon-like peptide-1 (GLP-1) receptor agonists, show promise in selected populations. Hospitalists play a critical role in early recognition, initiation of GDMT, and comprehensive management of comorbidities. This review aims to summarize current guideline-directed medical therapy (GDMT) for HFpEF and provide a practical framework for hospital-based management.<\/jats:p>","DOI":"10.56305\/001c.163599","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T12:52:43Z","timestamp":1782910363000},"source":"Crossref","is-referenced-by-count":0,"title":["Comprehensive Framework of Heart Failure with Preserved Ejection Fraction Management for Hospitalists: A Scoping Review"],"prefix":"10.56305","volume":"5","author":[{"given":"Jeffery","family":"Northway","sequence":"first","affiliation":[{"name":"Saint Louis University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Park","sequence":"additional","affiliation":[{"name":"Saint Louis University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Mankowitz","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05j8e7885","id-type":"ROR","asserted-by":"publisher"}],"name":"St. Luke's Hospital","department":["Division of Cardiology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farzana","family":"Hoque","sequence":"additional","affiliation":[{"name":"Saint Louis University School of Medicine","department":["Department of Medicine"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"35509","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"issue":"17","key":"ref1","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction","volume":"381","author":"S.D. Solomon","year":"2019","journal-title":"N Engl J Med"},{"issue":"15","key":"ref2","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for Heart Failure with Preserved Ejection Fraction","volume":"370","author":"B. Pitt","year":"2014","journal-title":"N Engl J Med"},{"issue":"9386","key":"ref3","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","article-title":"Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial","volume":"362","author":"S. Yusuf","year":"2003","journal-title":"Lancet Lond Engl"},{"issue":"23","key":"ref4","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1056\/NEJMoa0805450","article-title":"Irbesartan in Patients with Heart Failure and Preserved Ejection Fraction","volume":"359","author":"B. M. Massie","year":"2008","journal-title":"N Engl J Med"},{"issue":"12","key":"ref5","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1001\/jama.2013.2024","article-title":"Effect of Phosphodiesterase-5 Inhibition on Exercise Capacity and Clinical Status in Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial","volume":"309","author":"M. M. Redfield","year":"2013","journal-title":"JAMA"},{"issue":"11","key":"ref6","doi-asserted-by":"publisher","first-page":"e19398","DOI":"10.7759\/cureus.19398","article-title":"Role of Diabetes Mellitus in Heart Failure With Preserved Ejection Fraction: A Review Article","volume":"13","author":"O. Mgbemena","journal-title":"Cureus"},{"issue":"4","key":"ref7","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s00059-022-05123-9","article-title":"Comorbidities in heart failure with preserved ejection fraction","volume":"47","author":"A. Deichl","year":"2022","journal-title":"Herz"},{"issue":"12","key":"ref8","doi-asserted-by":"publisher","first-page":"100705","DOI":"10.1016\/j.xkme.2023.100705","article-title":"Heart Failure With Preserved Ejection Fraction With CKD: A Narrative Review of a Multispecialty Disorder","volume":"5","author":"R. N. Patel","year":"2023","journal-title":"Kidney Med"},{"issue":"10","key":"ref9","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1161\/CIRCRESAHA.121.318186","article-title":"Pathophysiology and Therapeutic Approaches to Acute Decompensated Heart Failure","volume":"128","author":"J. N. Njoroge","year":"2021","journal-title":"Circ Res"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"107863","DOI":"10.1016\/j.pharmthera.2021.107863","article-title":"The natriuretic peptide system in heart failure: Diagnostic and therapeutic implications","volume":"227","author":"K. Kuwahara","year":"2021","journal-title":"Pharmacol Ther"},{"issue":"10","key":"ref11","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1161\/CIR.0000000000000659","article-title":"Heart Disease and Stroke Statistics\u20142019 Update: A Report From the American Heart Association","volume":"139","author":"E. J. Benjamin","year":"2019","journal-title":"Circulation"},{"issue":"10","key":"ref12","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1161\/CIRCRESAHA.121.318159","article-title":"From Systemic Inflammation to Myocardial Fibrosis","volume":"128","author":"W. J. Paulus","year":"2021","journal-title":"Circ Res"},{"issue":"0","key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2025.02.014","article-title":"JCS\/JHFS 2025 Guideline on Diagnosis and Treatment of Heart Failure","volume":"0","author":"T. Kitai","year":"2025","journal-title":"J Card Fail"},{"issue":"36","key":"ref14","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"42","author":"T. A. McDonagh","year":"2021","journal-title":"Eur Heart J"},{"issue":"37","key":"ref15","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"44","author":"T. A. McDonagh","year":"2023","journal-title":"Eur Heart J"},{"issue":"10354","key":"ref16","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S0140-6736(22)01429-5","article-title":"SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials","volume":"400","author":"M. Vaduganathan","year":"2022","journal-title":"Lancet Lond Engl"},{"issue":"5","key":"ref17","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1093\/eurheartj\/ehab798","article-title":"Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction","volume":"43","author":"J. Butler","year":"2022","journal-title":"Eur Heart J"},{"issue":"5","key":"ref18","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1161\/CIRCULATIONAHA.119.044586","article-title":"Sacubitril\/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure","volume":"141","author":"S.D. Solomon","year":"2020","journal-title":"Circulation"},{"issue":"19","key":"ref19","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1001\/jama.2021.18463","article-title":"Effect of Sacubitril\/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction: The PARALLAX Randomized Clinical Trial","volume":"326","author":"B. Pieske","year":"2021","journal-title":"JAMA"},{"issue":"1","key":"ref20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jacc.2023.04.019","article-title":"Angiotensin-Neprilysin Inhibition in Patients With Mildly Reduced or Preserved Ejection Fraction and Worsening Heart Failure","volume":"82","author":"R. J. Mentz","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"ref21","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","article-title":"Regional variation in patients and outcomes in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial","volume":"131","author":"M. A. Pfeffer","year":"2015","journal-title":"Circulation"},{"issue":"18","key":"ref22","doi-asserted-by":"publisher","first-page":"e895","DOI":"10.1161\/CIR.0000000000001063","article-title":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"P. A. Heidenreich","year":"2022","journal-title":"Circulation"},{"issue":"15","key":"ref23","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","article-title":"Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes","volume":"390","author":"M. N. Kosiborod","year":"2024","journal-title":"N Engl J Med"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.116.309348","article-title":"Hypertrophic Obstructive Cardiomyopathy","author":"R. A. Nishimura","year":"2017","journal-title":"Circ Res"},{"issue":"10","key":"ref25","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s40265-022-01739-7","article-title":"Mavacamten: First Approval","volume":"82","author":"S. J. Keam","year":"2022","journal-title":"Drugs"},{"issue":"9","key":"ref26","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1016\/j.cardfail.2024.04.024","article-title":"Evolving Strategies for the Management of Obstructive Hypertrophic Cardiomyopathy","volume":"30","author":"L. W. Liang","year":"2024","journal-title":"J Card Fail"},{"issue":"19","key":"ref27","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1016\/j.jacc.2024.09.003","article-title":"Impact of Aficamten on Disease and Symptom Burden in Obstructive Hypertrophic Cardiomyopathy","volume":"84","author":"M. S. Maron","year":"2024","journal-title":"JACC"},{"key":"ref28","series-title":"StatPearls","article-title":"Transthyretin Amyloid Cardiomyopathy (ATTR-CM)","author":"A. Jain","year":"2025"},{"issue":"5","key":"ref29","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.jacc.2025.09.004","article-title":"Transthyretin Cardiac Amyloidosis Evaluation and Management: 2025 ACC Concise Clinical Guidance","volume":"87","author":"M. M. Kittleson","year":"2026","journal-title":"JACC"},{"issue":"11","key":"ref30","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy","volume":"379","author":"M. S. Maurer","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"ref31","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa2305434","article-title":"Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy","volume":"390","author":"J. D. Gillmore","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"ref32","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa2409134","article-title":"Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy","volume":"392","author":"M. Fontana","year":"2025","journal-title":"N Engl J Med"},{"issue":"5","key":"ref33","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3390\/jcdd11050148","article-title":"Heart Failure with Mildly Reduced Ejection Fraction\u2014A Phenotype Waiting to Be Explored","volume":"11","author":"A. Nair","year":"2024","journal-title":"J Cardiovasc Dev Dis"},{"issue":"8","key":"ref34","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1016\/j.cardfail.2025.03.017","article-title":"Acoramidis for Transthyretin Amyloid Cardiomyopathy: Open-Label Extension Study Long-Term Follow-Up","volume":"31","author":"A. Masri","year":"2025","journal-title":"J Card Fail"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1186\/s13098-025-01917-z","article-title":"Heart failure with preserved ejection fraction and obesity: emerging metabolic therapeutic strategies","volume":"17","author":"W. Zheng","year":"2025","journal-title":"Diabetol Metab Syndr"},{"issue":"19","key":"ref36","doi-asserted-by":"publisher","first-page":"6139","DOI":"10.3390\/jcm12196139","article-title":"Association between Obstructive Sleep Apnea and Heart Failure in Adults\u2014A Systematic Review","volume":"12","author":"A. Polecka","year":"2023","journal-title":"J Clin Med"},{"issue":"5","key":"ref37","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.jacc.2025.09.004","article-title":"Transthyretin Cardiac Amyloidosis Evaluation and Management: 2025 ACC Concise Clinical Guidance","volume":"87","author":"M. M. Kittleson","year":"2026","journal-title":"JACC"},{"issue":"2","key":"ref38","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s10741-022-10236-8","article-title":"Device therapy with interatrial shunt devices for heart failure with preserved ejection fraction","volume":"28","author":"S. Nanayakkara","year":"2023","journal-title":"Heart Fail Rev"},{"issue":"10","key":"ref39","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1056\/NEJMra2413445","article-title":"Hypertrophic Cardiomyopathy","volume":"393","author":"E. Braunwald","year":"2025","journal-title":"N Engl J Med"},{"issue":"9","key":"ref40","doi-asserted-by":"publisher","first-page":"539","DOI":"10.14744\/AnatolJCardiol.2023.3345","article-title":"Comparing the Diagnostic Performance of HFA-PEFF and H2FPEF Scoring Systems in Heart Failure with Preserved Ejection Fraction Patients: Insights from the APOLLON Registry","volume":"27","author":"G. \u00d6. Mert","year":"2023","journal-title":"Anatol J Cardiol"},{"issue":"4","key":"ref41","doi-asserted-by":"publisher","first-page":"e011351","DOI":"10.1161\/CIRCHEARTFAILURE.123.011351","article-title":"Iron Deficiency, Anemia, and Iron Supplementation in Patients With Heart Failure: A Population-Level Study","volume":"17","author":"M. Wahid","year":"2024","journal-title":"Circ Heart Fail"},{"issue":"1","key":"ref42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cells9010242","article-title":"Cellular and Molecular Differences between HFpEF and HFrEF: A Step Ahead in an Improved Pathological Understanding","volume":"9","author":"S. J. Simmonds","year":"2020","journal-title":"Cells"},{"issue":"13","key":"ref43","doi-asserted-by":"publisher","first-page":"7106","DOI":"10.3390\/ijms22137106","article-title":"RAAS: A Convergent Player in Ischemic Heart Failure and Cancer","volume":"22","author":"T. C. Garcia-Gardu\u00f1o","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"5","key":"ref44","first-page":"452","article-title":"Evidence-Based Heart Failure Management: A Practical Guide for Hospitalists","volume":"124","author":"J. Northway","year":"2025","journal-title":"WMJ Off Publ State Med Soc Wis"},{"issue":"16","key":"ref45","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction","volume":"391","author":"S.D. Solomon","year":"2024","journal-title":"N Engl J Med"},{"issue":"9","key":"ref46","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1161\/CIRCULATIONAHA.122.059785","article-title":"Empagliflozin for Heart Failure With Preserved Left Ventricular Ejection Fraction With and Without Diabetes","volume":"146","author":"G. Filippatos","year":"2022","journal-title":"Circulation"},{"issue":"12","key":"ref47","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction","volume":"387","author":"S.D. Solomon","year":"2022","journal-title":"N Engl J Med"}],"container-title":["Journal of Brown Hospital Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bhm.scholasticahq.com\/article\/163599-comprehensive-framework-of-heart-failure-with-preserved-ejection-fraction-management-for-hospitalists-a-scoping-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T12:52:44Z","timestamp":1782910364000},"score":1,"resource":{"primary":{"URL":"https:\/\/bhm.scholasticahq.com\/article\/163599-comprehensive-framework-of-heart-failure-with-preserved-ejection-fraction-management-for-hospitalists-a-scoping-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":47,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.56305\/001c.163599","relation":{},"ISSN":["2994-5593"],"issn-type":[{"value":"2994-5593","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]}}}